Welcome to our dedicated page for Biodexa Pharmaceuticals news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals stock.
Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Biodexa Pharmaceuticals PLC has issued an additional 10,508,394 Pre-Funded Warrants, increasing the total to 12,444,558 under its Private Placement. The issuance follows a calculation based on 90% of the volume-weighted average prices from the preceding five trading days. Each warrant is immediately exercisable into one new ADS (equivalent to five new Ordinary Shares) at an exercise price of US$0.0004. The announcement is tied to a previously disclosed consolidation and ratio change.
Biodexa Pharmaceuticals PLC (AIM:BDRX; Nasdaq:BDRX) announced the issuance of 7,473,095 new ordinary shares following the exercise of 848,068 A Warrants and 646,551 B Warrants on a cashless basis. This transaction will increase the company's issued share capital to 16,140,432 ordinary shares, effective April 3, 2023. The new shares will rank pari passu with existing shares and serve as the denominator for shareholders to assess any changes in their interest. This move may influence shareholder stakes, but no treasury shares are held by the company.